分享两篇SCI发表的经历(coverletter、responseletter)

1、分享两篇SCI发表的经历三年前对于我来说SCI就是天书一样，在我踏进博士的门槛后我以为自己进 入了地狱，也纠结也彷徨，整天刷虫友们对于博士、SCI的帖子，我选择了虫友们鼓励的那一部分来激励自己继续前行。我告诉自己坚持就是胜利，当然那是积极的坚持。在好几月之前就有这个想法，今天早上收到第二篇的接收通知后，我便想今天一定要在小木虫上谢谢那些给予我帮助的虫友们。话不多说，我把自己这两篇投稿的经历与大家共享，希望能给大家带来一点点用处。第一篇发表在FitoterapiaCover letterDear Editor Verotta:We would like to submit the manuscr

2、ipt entitled "xxxxx题目"：by xxxxx所有作者姓名 which we wish to be considered for publication in Journal of Fitoterapia.All authors have read and approved this versi on of the article, and due care has been taken to ensure the integrity of the work. Neither the entire paper nor any part of its cont

3、ent has been published or has been accepted elsewhere. It is not being submitted to any other journ al.We believe the paper may be of particular in terest to the readers of your journalas it is the first time ofxxxxx 研究的精华所在Thank you very much for your rec on sideri ng our revised manu script for po

4、tential publication in Fitoterapia. We are looking forward to hearing from you soon. Correspondence should be addressed to Jinhui Yu at the following address, phone and fax number , and email address.地址、学院、学校名称Pho ne: + 86 xxxxxFax number: + 86571 xxxxxEmail address:xxxxxBest wishes for you and your

5、 family!Sin cerely yours,xxx所有作者Resp onse to reviewersDear Editor:Thank you very much for your letter and the comme nts from the referees aboutour paper submitted to Journal of Fitoterapia (FITOTE-D-11-01071). The manuscript entitled " xxxxxx" by xxxxxx所有作者 have been revised accord ing to

6、the reviewers' comme nts, and we wish it to be rec on sidered forpublicati on in Journal of Fitoterapia.A list of cha nges and resp on ses to reviewers are as follows.List of ActionsLOA1: The key words were cha nged in page?.LOA2: The n ame and locati on of the local biochemistry compa ny have b

7、ee nadded in sect ion 2.1 (page 3).LOA3: A paragraph has bee n added in secti on 3.1 (page 5) to further expla inthe determ in ati on of the cis and trans con figurati on of double bonds in polypre no Is.LOA4: The Ianguage was improved by English Ianguage editing of Elsevier webshop.To Reviewer 1#,T

8、hank you very much for pointing out the problems in our manuscript. We have revised it accord ing to your recomme ndati ons. We would like to know if there are still somewhere n eed to be ame nded.(1) Keywords: gen eral terms should be avoided; I would cha nge some of thekeywords (homologues, identi

9、fication, quantification)The key words have bee n cha nged as follows:xxxxx修改后关键词(2) In paragraph 2.1 the "local biochemistry company" should be identified byn ame and locati on.The n ame and locati on of the local biochemistry compa ny have bee n added in section 2.1 (page 3). NaOH , Pyro

10、gallol, an hydrous Na2SO4 were purchased from Han gzhou Changqin gHuag ong CO., LTD.(3) How the cis and trans configuration of double bonds in xxxxxx were determ in ed? Authors should say someth ing about.The following paragraph has been added in section 3.1 (page 5) to further expla in the determ i

11、n ati on of the cis and trans con figurati on of double bonds in xxxxxx .(4) Lan guage should be checked for clarity and correct ness.The Ian guage was improved by En glish Ian guage edit ing of Elsevier webshop.To Reviewer 2#,Thank you very much for your recommendation on our paper and we have impr

12、oved by En glish Ian guage edit ing of Elsevier webshop.All in all, tha nk you very much for your rec on sideri ng our revised manu script for potential publication in Fitoterapia. rm looking forward to hearing from you soon. Correspondence should be addressed to * 第一作者或通讯作者atthe follow ing address,

13、 pho ne and fax nu mber, and email address.地址Pho ne: + 86571xxxxxFax number: +xxxxxEmail address:xxxxxlBest wishes for you and your family!Sin cerely yours,xxxxx x所有作者总的来说，第一篇文章没有费很大劲。投稿后二个月左右便有消息，小修后提交，第二天便接收了！那是因为这篇文章是历经磨难后的， 之前投了Separat ion ofscience和JPEA,其中第一个期刊当天就给我回复了，那肯定是悲剧的！编辑所谓的与该期刊不符，但我认为主

14、要是因为文章写的太垃 圾，那是我第一次写SCI而且是没有任何人指点的情况下，可想而知会有多烂。随后这篇文章放了将近一年，填补了写数据，又投了第二个期刊，编辑委婉的拒 了但给我修改重投的机会。我按照审稿人的意见和建议修改了几个月后重投（补 数据，重新整结构框架，仅次于重写），结果悲剧了。而且不是因为修改的问题， 而是说我的文章档次太低，不足以在JPEA上发表，我当时晕倒怎么不早说， 害我这么长时间的重修。不过现在想想若不是重修在下次的投稿中又怎能如此顺 利呢？所以说所有的努力都不是白费的！第二篇投了 Journal of Ethnopharmacology，相比第一篇这个稍有磨难。也是差 不多两

15、个月的样子收到修改意见，修改后提交一直不见动静，等两个月左右的时 候我有点hold不住了，编发了一封催稿信，之前看论坛里说忌讳催稿，但也 看期刊吧，Journal of Eth nopharmacology 的编辑第二天便给了修改建议（还是 要修改），原因是第一次修改是一个审稿人的，由于另外一个审稿人一直没给才 拖到第二次。也没办法，只能再改！这次相对比较快点，每到一个月便通知接收 了。Journal of Ethnopharmacology 与别的期刊不同，有一份 Author_checklist。不 算重要但还是给大家附上附件吧（黏贴好像乱掉了），我之前也是请教的虫友。 需要提醒的是初次提

16、交和修改后要注意最后一项打勾。Dear editor,We would like to submit the manuscript entitled " xxxxxx' 'by xxxxxx which we wish to be con sidered for publicati on in Jour nal of Eth nopharmacology.All authors have read and approved this versi on of the article, and due care hasbeen taken to ensure the in

17、tegrity of the work. Neither the entire paper nor anypart of its content has been published or has been accepted elsewhere. It is not being submitted to any other journ al.We believe the paper may be of particular in terest to the readers of your journalas it is the first time of in vestigat ingxxxx

18、xxCorrespondence should be addressed to Jinhui Yu at the following address, phone and fax number , and email address.地址Pho ne: + 86xxxxxFax number: + 86571 xxxxxEmail address:xxxxxThank you very much for your considering our manuscript for potential publication. I'm looking forward to hearing fr

19、om you soon.Best wishes for you and your family!Sin cerely yours,xxxxxx大同小异单独提交 revisionnotes第一次修改A list of cha nges and resp on ses to reviewers are as follows.List of ActionsL0A1: The refere nee on the selecti on of doses has bee n adapted in secti on 2.2 (page 5).L0A2: The details of HPLC data we

20、re suppleme nted in sect ion 2.1 (page 4).L0A3: Figure 3, figure 4 and figure 5 have been redrawn.Replies to the remarks of the reviewer 1:The authors appreciate valuable suggestions and comments from the anonym ous reviewers. We have revised our manu script accord in gly. Hope it is satisfactory no

21、w. How the doses have bee n selected? If the doses have bee n adapted from a previous publicati on please cite the paperThe doses were selected accordi ng to previous studies ofxxxxx0 We haveadapted the paper in our revised manu script.(2) It would be more in teresti ng if the authors could show the

22、 details of HPLCdata in this manu script. Which fract ion has bee n used to perform experime nts? We have provided the HPLC chromatogram of xxxxx used in the animal experime nt. The fracti on of the purified extract mostly con sisted ofxxxxx,which accounting for 0.22%,1.06%,5.65%,13.96%,10.82%,6.70%

23、,14.47%, 22.81%,16.64%, 6.13%, 1.52%, respectively. The purity of thexxxxxx was assessed using HPLC, amounting to > 85%.(3) Fig 3 and 5 should be red one. Photos may take by using little more higher objectives like 32X or 40 X to show the picture clearly. Scale bars should be men ti oned in side

24、the figure (in right corn er).We redrew the both figures. Scale bars have bee n men tio ned in side the figure 3, figure 4 and figure 5. The magn ificati on of 200 was adopted for figure 3 and figure 5, referri ng to many previous studies (Gui et al., 2006; Hsieh et al., 2011;Jung et al., 2012; Xiao

25、 et al., 2012). The reviewer's concern about the in sufficie ntly clear figures might result from the low resoluti on of the picture in our previous version. Corresponding pictures with improved resolution were provided, which appear much clearer . We can also provide original figures if it is n

26、 ecessary.Refere nces:Gui, S.Y., Wei, W., Wang, H., Wu, L., Sun, W.Y ., Chen, W.B. and Wu, C.Y ., 2006.Effects and mecha ni sms of crude astragalosides fractio n on liver fibrosis in rats.Journal of Eth nopharmacology 103: 154-159.Hsieh, W.T., Liu, Y.T. and Lin, W.C., 2011. Anti-inflammatory propert

27、ies of Ajugabracteosa in vivo and in vitro study and their effects on mouse model of liver fibrosis. Journal of Eth nopharmacology 135: 116-125.Jung, H.W., Jung, J.K., Son, K.H., Lee, D.H., Kang, T .M., Kim, Y.S. and Park, Y.K., 2012. In hibitory effects of the root extract of Dipsacus asperoides C.

28、Y . Cheng et al t.m.ai on collage n-i nduced arthritis in mice. Jour nal of Eth nopharmacology 139: 98-103.Xiao, J., Lio ng, E.C., Chi ng, Y.P., Cha ng, R.C., So, K.F., Fung, M.L. and Tipoe, G.L., 2012. Lycium barbarum polysaccharides protect mice liver from carb on tetrachloride-induced oxidative s

29、tress and necroinflammation. Journal of Eth nopharmacology 139: 462-470.Yu, J., Wang, Y, Qian, H., Zhao, Y, Liu, B. and Fu, C. Polyprenols from the needles of Taxus chinensis var . mairei. Fitoterapia, in revison.第二次修改A list of cha nges and resp on ses to reviewers are as follows.List of ActionsLOA1

30、: The descripti on of the effect of TPs (protective rather tha n therapeutic)in the article was corrected to avoid misun dersta nding.In troducti on, the last sentence (paragraph 3).Section 3.1,“ Rats treated with TPs” was changed as“ Rats treated with bothTPs and CCl4 ” (li ne 3)Sectio n 3.5,“in th

31、e livers of chronic CCl4 treated rats” was deleted by ad“In the treatme nt with TPs+CCl4” at the head of the senten ce. (li ne 7)Discussi on, the first and the last sentence (paragraph 1).Discussion, “ thetreatment with TPs” was changed as “ thetreatment withTPs+CCl4 ” (paragraph 2, line 9)Discussi

32、on, the last sentence (paragraph 4)Discussi on, the last sentence (paragraph 5)Discussi on, the first sentence (paragraph 7)LOA2: The figures and tables are explained in order in the main text.Section 3.1, Fig. 3A (line 6) was added.Section 3.3, Fig. 4A (line 2), Fig. 4B-C (line 3) and Fig. 4B (line

33、 9) and Fig. 4A-B (li ne 10) were deleted.Section 3.4, Fig. 5A, F (line 3), Fig. 5C-E, F (line 5) were added.LOA3: Figure 2 was supplemented with the standard chromatogram and con crete in formati on about the peaks un der the figure.LOA4: The petroleum was corrected into petroleum ether .LOA5: The

34、discussi on sect ion was modified.Replies to the remarks of the reviewer 2:The authors appreciate valuable suggestions and comments from the anonym ous reviewers. We have revised our manu script accord in gly.1. Fig 6 shows thatxxxx on RNA expressi on is not dose depe nden t, ratherdifferent doses o

35、fxxxxx has opposite effect ( Fig 6 A, E,K), means thatprotein level of this gene could provide the missing links. According to me protein level along with RNA level could provide an in sight to the mecha nism of xxxxxx .We agree with this point. We have actually tried qua ntitative an alyses of rela

36、tive proteins to further clarify mechanism, as well as Western-Blot experiments. These efforts, however, failed due to the technical difficulty of removing the lipid compositi on which seriously in terfere the accuracy of prote in qua ntificati on. After the optimizatio n and improveme nt of the ext

37、ract ion for quite a long time, the experime ntal result was still not satisfactory. However , we believe our present results could fairly although not perfectly support our main con clusi ons. Any way, we cha nged several in terpretati ons of the prese nt results to adequately discuss the mechanism

38、s of xxxxx。x2. In the conclusion, the authors claimed that " the possible mechanism invoIves an anti oxidative ability.". According to the Table 4 data, it is evidentthat lipid peroxidatio n of xxxxxx 120 and 300 are same ( in sig nifica ntly different) but corresponding antioxidant enzyme

39、 activities were significantlydiffer betwee n them.The incon siste nt results betwee n an tioxida nt en zyme activities and lipid peroxidati on might n eed some expla natio n. As we know, the compositi on of the lipid peroxidati on which in cludes many other comp onents (Loidl-Stahlhofe n and Spitel

40、ler, 1994) except malondialdehyde might have been changed under xxxxxx 300 treatment. Moreover, the antioxidant mechanism of different drugs in various orga ni sms is completed accordi ng to previous studies (Gala no et al., 2009; Qia n et al., 2011). We just speculate that the an ti-fibrotic effect

41、 might be related with the antioxidant ability of the xxxxx based on txe data, while the prelimi nary con clusi on n eeds further experime ntal verificati ons. We have made corresp onding modificati on on the con clusi on in our manu script.3. I am con fused with the durati on of xxxxxx in an imals.

42、 In ducti on of cirrhosis was done by subcuta neous injectio n of CCI4 for 8weeks. Simulta neous admi nistrati on of drug was performed for 8weeks. Can I assume that the acti onof drug is to preve nt the in duct ion of cirrhosis rather tha n therapeutic effect?The experime nt only verified the preve

43、 ntive effect rather tha n the therapeutic effect. We will con sider the therapeutic effect in the n ext experime nt. We have corrected the descripti on in the article to avoid misun dersta nding4. The figures and Tables are not expla ined in order , in the main text.We have carefully checked the wh

44、ole text and corrected the issues you raised.5. Fig 2, chromatogram of sta ndard is miss ing, expla nati on of differe nt peaks are also miss ingWe have supplied the sta ndard chromatogram in Figure 2, and appe nded the particular in formatio n of each peak, in clud ing the n ame of the substa nee a

45、nd the perce ntage.6. Expressi on of "p value" is mislead ingWe are sorry that we have not comprehe nded your meaning. The expressi on of "p value" in our manuscript was referred to literatures (Kim et al., 2011; Li et al., 2010).7. I n the method secti on, in stead of petroleum,

46、 petroleum ether would givebetter percepti on.We are sorry about the mistake. Actually, we used petroleum ether in the experime nt.8. Tests like In docya nine gree n plasmadisappeara neerate/mono ethylglyci nexylidide test would be more sen sitive tests for liver fun ctio nWe selected the in dicator

47、s and methods for liver function evaluati on accordi ng to the published literature on animal experiments (Li et al., 2010; Mu et al., 2009; Takahashi et al., 2012; Tipoe et al., 2010). They are also well accepted as in dicators in this field. In docya nine gree n plasma disappeara nee rate/monoethy

48、lglycinexylidide test are mainly in clinical use. We will consider its applicati on in our further studies.9. The mechanism ofxxxxx is not properly discussed.We have endeavored to sort out the mechanism of xxxxxx via further revision of the corresponding discussion. The authors would appreciate that

49、 reviewers could explicitly state the points in case of further concerns. We promise to address them immediately.10. Authors suggested in the limitatio n of the study that xxxxx is not higly x pure, still it shows better activity than standard drug, not in histopathology results.Thanks for highlight

50、i ng our findin gs.xxxxx are>promisi ng n atural productsdeserving further investigations. Actually we are currently optimizing the purified process to prepare high-purity xxxxxx for post verification experime nt.Refere nces:Gala no, A., a lvarez-Diduk, R., Ramirez-Silva, M.T., Alarc o n- a n gebs,a nd Rojas-Hern a ndeA., 2009. Role of the reacting free radicals on the an tioxida ntmecha nism of curcu min. Chemical Physics 363, 13-23.Kim, H.Y., Park, J., Lee, K.H., Lee, D.U